Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20533360 | 1.00 | KMT2A (0.43) | KMT2AMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL25171844 | 1.00 | KMT2A (0.43) | KMT2AMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL922178 | 0.73 | MAPT (0.57) | KMT2AMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL15720603 | 0.70 | MAPT (0.46) | KMT2AMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL15720604 | 0.70 | MAPT (0.46) | KMT2AMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL29629563 | 0.67 | MAPT (0.43) | KMT2AMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL9422003 | 0.65 | CYP1B1 (0.50) | KMT2AMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL9422004 | 0.65 | CYP1B1 (0.50) | KMT2AMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL4770419 | 0.64 | SRD5A2 (0.59) | RAB9APOLBHPGDATM | |
| SCHEMBL20852084 | 0.64 | MAPT (0.57) | KMT2AMAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3350184-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | LOXO ONCOLOGY INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC. (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | KMT2A 927/4885MAPT 4405/4885RAB9A 3456/4885 |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | KMT2A 927/4885MAPT 4405/4885RAB9A 3456/4885 |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | KMT2A 927/4885MAPT 4405/4885RAB9A 3456/4885 |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | KMT2A 927/4885MAPT 4405/4885RAB9A 3456/4885 |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | KMT2A 927/4885MAPT 4405/4885RAB9A 3456/4885 |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | KMT2A 927/4885MAPT 4405/4885RAB9A 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.